
Roche

Roche

HY 2016 results

Basel, 21 July 2016

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production;
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

Group

Severin Schwan

Chief Executive Officer

HY 2016 performance

Outlook

HY 2016: Highlights

Growth

Sales	• Group sales +5%[1]
Profit	• +5% Core EPS growth[1]

Portfolio progress Q2

Oncology	• Cancer immunotherapy: Tecentriq launched in bladder cancer (US), filed in lung cancer (US, EU) • Venclexta launched in US (CLL 17p del)
Hematology	• Gazyva: Phase III (GALLIUM) in iNHL, met primary endpoint at interim • Gazyva: Phase III (GOYA) in aNHL, not superior to MabThera/Rituxan • Emicizumab (ACE 910): Ph III in patients with FVIII inhibitors fully recruited
Neuroscience	• OCREVUS: Filings accepted in EU and US; PDUFA date Dec 28, 2016
Immunology	• Actemra: Ph III in giant cell arteritis met primary end point • Xolair: Paediatric approved in US
Diagnostics	• Launch of cobas e801, high throughput immunodiagnostics analyser

[1] All growth rates at constant exchange rates (CER)

Investing into a growing business

First Half 2016

- Launches off to a good start
  - Pharma: Cotellic, Alecensa, Venclexta, Tecentriq
  - Dia platforms: cobas e801, Ventana HE600
- Substantial investment into new business
  - Pharma: - **5 NME launches in a year**
    - investments in cancer immunotherapies
  - Dia: Investments in molecular diagnostics solutions
  - Expansion of biologics manufacturing network
- Benefit from PSI* (CHF 426m)

Outlook Full Year 2016

- One-off PSI* effect diluted on full year basis; positive base effect on costs H2 2015
- Ongoing productivity measures
- Core EPS growth > sales growth

* Past service income

HY 2016: Strong sales growth in both divisions

	HY 2016 CHFbn	HY 2015 CHFbn	Change in % CHF	Change in % CER
Pharmaceuticals Division	**19.5**	18.4	**6**	**4**
Diagnostics Division	**5.6**	5.2	**6**	**6**
Roche Group	**25.0**	23.6	**6**	**5**

CER=Constant Exchange Rates

Q2 2016: Sales growth for fifth consecutive year



All growth rates at Constant Exchange Rates (CER)

HY 2016: Strong sales growth in all regions



All growth rates at Constant Exchange Rates (CER)

HY 2016: Strong core operating profit & margin



CER=Constant Exchange Rates

HY 2016: Core EPS growth above sales growth



All growth rates at Constant Exchange Rates (CER)

Continued leadership in innovation

Launches at historical high

5 NME launches in a year



Roche significantly advancing patient care

Recognition for innovation 2013-present

12 *Breakthrough Therapy Designations*

Rank	Company	#
1	**Roche**	**12**
2	Novartis	10
3	BMS	9
4	Merck	6
5	Pfizer	6
6	Abbvie	6

Year	Molecule
2016	***Ocrelizumab*** *(PPMS)*
	Venclexta *(AML)*
	Venclexta + Rituxan *(R/R CLL)*
2015	***Actemra*** *(Systemic sclerosis)*
	Tecentriq *(NSCLC)*
	Venclexta *(R/R CLL 17p del)*
	Emicizumab*/ACE 910 (Hemophilia A)*
2014	***Esbriet*** *(IPF)*
	Lucentis *(Diabetic retinopathy)*
	Tecentriq *(Bladder)*
2013	***Alecensa*** *(2L ALK+ NSCLC)*
	Gazyva *(1L CLL)*

Source: http://www.focr.org/breakthrough-therapies as at July 2016; PPMS=Primary Progressive Multiple Sclerosis; CLL=Chronic Lymphocytic Leukemia; NSCLC=Non-Small Cell Lung Cancer; IPF=Idiopathic Pulmonary Fibrosis

Significant launch activities ahead



Outcome studies are event-driven: timelines may change. Standard approval timelines of 1 year assumed.

2016 outlook

Group sales growth[1]	Low to mid-single digit
Core EPS growth[1]	Ahead of sales growth
Dividend outlook	Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Pharmaceuticals Division

Daniel O'Day

CEO Roche Pharmaceuticals

HY 2016 results

Innovation

Outlook

HY 2016: Pharma sales

Good growth in all regions

	HY 2016 CHFm	HY 2015 CHFm	Change in % CHF	Change in % CER
Pharmaceuticals Division	**19,460**	**18,350**	**6**	**4**
United States	9,273	8,586	8	4
Europe	4,639	4,291	8	5
Japan	1,756	1,540	14	2
International	3,792	3,933	-4	4

CER=Constant Exchange Rates

HY 2016: Pharma Division

Core operating profit growth +5%

	HY 2016 CHFm	HY 2016 % sales
Sales	**19,460**	**100.0**
Royalties & other op. inc.	926	4.8
Cost of sales	-3,868	-19.9
M & D	-3,039	-15.6
R & D	-4,129	-21.2
G & A	-366	-1.9
Core operating profit	**8,984**	**46.2**



CER=Constant Exchange Rates; CIT=cancer immunotherapy

HY 2016: Strong performance from oncology and immunology franchises



Absolute values and growth rates at Constant Exchange Rates (CER)

HY 2016: Oncology launches off to a good start



- Strong uptake of Perjeta and Kadcyla
- Growth of Herceptin due to longer treatment

- Growth driven mainly by CRC, ovarian and cervical

- Gazyva: US/EU approval in R/R iNHL (GADOLIN);
- Positive results in 1L iNHL (GALLIUM);
- Not superior to MabThera in 1L aNHL (GOYA)

- Increased competition
- EU: Avastin+Tarceva in 1L NSCLC approved

- Loss of exclusivity

- Back to growth post launch of Cotellic

- US: Launch off to a strong start
- Japan: Continued strong growth (J-ALEX study)

CER=Constant Exchange Rates
HY 2016 Oncology sales: CHF 12.4bn; CER growth +5%

HER2 franchise: Growth driven by Perjeta with Herceptin



HER2 franchise Q2 2016

- Perjeta (+35%): Strong demand due to ongoing neoadjuvant uptake in the EU
- Herceptin (+5%): Longer treatment duration in combo with Perjeta
- Kadcyla (+10%): Growth driven by all regions

Outlook 2016

- Herceptin: Further SC conversion
- Perjeta: Further increasing penetration
- Kadcyla: New launch countries
- Ph III APHINITY (adj. HER2+ BC) expected

CER=Constant Exchange Rates

SC conversion rates for Herceptin and MabThera

Herceptin conversion rate approaching 50%

SC share of Herceptin sales in launched countries*



SC share of MabThera sales in launched countries*



* Conversion rate charts exclude latest launch countries: Herceptin SC has been launched in 53 countries (Q1/16 launches in Argentina, Mexico and Hong Kong excluded); MabThera SC has been launched in 16 countries (Q1/16 launch in Spain excluded)

SC=subcutaneous

Avastin: International and Europe drive growth



Avastin Q2 2016

- Lung cancer: Driven by positive launch in China, and A+T in Europe
- Cervical and ovarian cancer: Strong growth in Europe
- Mesothelioma: Filing discussions underway

Outlook 2016

- Continued uptake in ovarian, cervical and lung cancer (A+T in EU)

CER=Constant Exchange Rates

Immunology: Franchise approaching CHF 8bn sales annualised



Immunology Q2 2016

Xolair (+17%)

- Continued strong uptake in allergic asthma & chronic idiopathic urticaria
- Paediatrics approval in asthma (US)

Actemra (+21%)

- Increasing 1L monotherapy leadership focusing on MTX intolerant patients
- Positive Ph3 results in giant cell arteritis

MabThera/Rituxan (+6%)

- Continues to grow in rheumatoid arthritis and vasculitis (GPA and MPA)

CER=Constant Exchange Rates; GPA=granulomatosis with polyangiitis; MPA=microscopic polyangiitis

Esbriet: Focus on mild and moderate patient segments



US (+32%)

- Growth driven by continued penetration into more severe patient segments

EU (+9%)

- Increasing differentiation due to strengthened label including the pooled 1 year mortality data

Outlook 2016

- Targeting mild and moderate patient segments

HY 2016 results

Innovation

Outlook

Ocrelizumab: FDA granted priority review for BLA

First drug active in both RMS & PPMS

Phase III (OPERA I/II) in RMS



Phase III (ORATORIO) in PPMS

FDA BTD



- Marketing applications for OCREVUS (ocrelizumab) in RMS and PPMS accepted by EMA and FDA
- PDUFA date: December 28th

BLA=biologic license application; BTD=breakthrough therapy designation; RMS=relapsing forms of multiple sclerosis (MS) which includes patients with RRMS and SPMS with superimposed relapses; RRMS=relapsing-remitting MS; SPMS=secondary progressive MS; PPMS=primary progressive MS; Adapted from Lublin 1996, Arnold 2004

Hematological cancers

Incidence cases reach 330,000 patients[1]



GAZYVA obinutuzumab injection

Rituxan Rituximab

VENCLEXTA venetoclax tablets

TECENTRIQ atezolizumab

COTELLIC (cobimetinib) tablets

aCD20/CD3 TCB

polatuzumab vedotin (anti-CD79b ADC)

idasanutlin (MDM2 antagonist)

LSD1 inhibitor

MDM2 antagonist prodrug

= Roche marketed **= Roche in development**

[1] Datamonitor; incidence rates includes the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); NHL=non-hodgkin`s lymphoma; DLBCL (aNHL)=diffuse large B-cell lymphoma; FL (iNHL)=follicular lymphoma; ALL=acute lymphoblastic leukemia; AML=acute myeloid leukemia; CLL=chronic lymphoid leukemia; MM= multiple myeloma; MDS=myelodysplastic syndrome; Venclexta in collaboration with AbbVie; Cotellic in collaboration with Exelixis; Gazyva in collaboration with Biogen; polatuzumab vedotin in collaboration with Seattle Genetics; LSD1inhibitor in collaboration with Oryzon Genomics

Development program in NHL

Five new medicines in combination testing

	Compound	Combination	Study name	Indication	Ph1 Ph2 Ph3	
NHL	***Gazyva***	*+bendamustine*	*GADOLIN*	FL (iNHL) (Rituxan refractory)		✓
	Gazyva	*+CHOP*	*GOYA*	1L DLBCL (aNHL)		✗
	Gazyva	*+chemo*	*GALLIUM*	1L FL (iNHL)		✓
	Venclexta*	***+Rituxan/+Rituxan****+bendamustine*	*CONTRALTO*	R/R FL (iNHL)		
	Venclexta	***+Rituxan****+CHOP****/Gazyva****+CHOP*	*CAVALLI*	1L DLBCL (aNHL)		
	Venclexta	***+Rituxan****+bendamustine*		R/R NHL		
	Venclexta			R/R CLL and R/R NHL		
	Venclexta	***+Gazyva+polatuzumab***		R/R DLBCL (aNHL) and R/R FL (iNHL)		
	polatuzumab	***+Rituxan/Gazyva***	*ROMULUS*	R/R DLBCL (aNHL) and R/R FL (iNHL)		
	polatuzumab	***+Gazyva/Rituxan+bendamustin***		R/R DLBCL (aNHL) and R/R FL (iNHL)		
	polatuzumab	***+Gazyva+CHP/Rituxan+CHP***		1L DLBCL (aNHL)		
	polatuzumab	***+Gazyva****+lenalidomide*		R/R DLBCL (aNHL) and R/R FL (iNHL)		
	Tecentriq	***+Gazyva*** *or +tazemetostat1***		R/R DLBCL (aNHL) and R/R FL (iNHL)		
	Tecentriq	***+Gazyva****+lenalidomide*		R/R FL (iNHL)		
	Tecentriq	***+Gazyva****+bendamustine or CHOP*		1L FL (iNHL) and 1L DLBCL (aNHL)		
	Tecentriq	***+Gazyva+polatuzumab***		R/R DLBCL (aNHL) and R/R FL (iNHL)		
	idasanutlin	***+Gazyva***		R/R DLBCL (aNHL) and R/R FL (iNHL)		

iNHL=indolent non-hodgkin`s lymphoma; aNHL=agressive NHL; CHOP=cyclophosphamide, doxorubicin, vincristine and prednisone; * Venclexta in collaboration with AbbVie; Gazyva in collaboration with Biogen; polatuzumab in collaboration with Seattle Genetics; **External collaboration

Development program in CLL, MM, AML, MDS

High unmet need in many indications

	Compound	Combination	Study name	Indication	Ph1 Ph2 Ph3	
CLL	***Gazyva***	*+chemo*	*CLL11*	CLL		✓
	Gazyva	*+FC/bendamustin/Clb*	*GREEN*	CLL and R/R CLL		
	Venclexta	***+Rituxan***		R/R CLL and SLL		
	Venclexta	***+Gazyva***	*CLL14*	CLL		
	Venclexta	***+Rituxan***	*MURANO*	R/R CLL		
	Venclexta			R/R CLL 17p		✓
	Venclexta			R/R CLL after ibru/idel		
	Venclexta	***+Rituxan****+bendamustine*		R/R CLL and untreated CLL		
	Venclexta	***+Gazyva***		R/R CLL and untreated CLL		
MM	***Venclexta***			R/R MM		
	Venclexta	*+bortezomib+dexamethasone*		R/R MM		
	Tecentriq	*+/-daratumumab** or +/-lenalidomide or +lenalidomide+daratumumab*		R/R MM		
AML	***Venclexta***			AML		
	Venclexta	*+decitabine/+azacitidine*		AML		
	Venclexta	***+Cotellic +idasanutlin***		R/R AML unfit for chemo		
	LSD1 inhibitor			AML		
	idasanutlin	*+cytarabine*		R/R AML		
	MDM2 ant. prodrug			AML		
MDS	***Tecentriq***	*+azacitidine*		MDS		
	aCD20/CD3 TCB			Hematologic tumors		

CLL=chronic lymphoid leukemia; R/R CLL=relapsed/refractory CLL; MM=multiple myeloma; AML=acute myeloid leukemia; FC=fludarabine, cyclophosphamide; LaAraC=low dose cytarabine; * Venclexta in collaboration with AbbVie; Gazyva in collaboration with Biogen; Cotellic in collaboration with Exelixis; **External collaboration

Tecentriq off to a good start

All-comers label in 2L+ bladder cancer

TECENTRIQ™
atezolizumab INJECTION FOR INTRAVENOUS USE 1200 mg

IMvigor210 study design



Cohort 1	IC2/3 (n = 32)	IC1/2/3 (n = 80)	all (n = 119)
ORR	28%	25%	24%
CR	6%	6%	7%
PR	22%	19%	17%

approved

Cohort 2	IC2/3 (n = 100)	IC1/2/3 (n = 207)	all (n = 310)
ORR	28%	19%	16%
CR	15%	9%	7%

- First and only aPD-L1 approved for locally advanced or metastatic bladder cancer
- First sales of CHF 19m recorded
- Update at ESMO for both cohort 1 (1L) and cohort 2 (2L+)

CIT development program by tumor type

Solid tumors

Solid tumors

Tecentriq		Ph1
Tecentriq	±chemo ±Avastin	Ph1
Tecentriq	+Cotellic	Ph1
aOX40	±Tecentriq	Ph1
aCEA/CD3 TCB	±Tecentriq	Ph1
IDOi	±Tecentriq	Ph1
emactuzumab	±Tecentriq	Ph1
aCEA-IL2v FP	±Tecentriq	Ph1
aFAP-IL2v FP		Ph1
aCD40	±Tecentriq	Ph1
emactuzumab	±aCD40	Ph1
aCD40	+vanucizumab	Ph1
Tecentriq	+vanucizumab	Ph1
aTIGIT	±Tecentriq	Ph1
Tecentriq	+daratumumab*	Ph1
Tecentriq	+IFN or ipilimumab*	Ph1
Tecentriq	+A2Ai*	Ph1
Tecentriq	+varlilumab*	Ph1

Bladder

Tecentriq	(2L+ UBC)	✓
Tecentriq	+BCG (NMIBC)	Ph1
Tecentriq	(2L+ UBC)	**Ph3**
Tecentriq	(Dx+ adjuvant MIBC)	**Ph3**
Tecentriq	+ chemo (1L mUC)	**Ph3**

Lung (NSCLC & SCLC)

Tecentriq	(2L/3L)	Ph2 filed/ **Ph3**
Tecentriq	(1L Dx+)	**Ph3**
Tecentriq	+chemo (3x 1L trials)	**Ph3**
Tecentriq	+chemo ±Avastin (1L)	**Ph3**
Tecentriq	(adjuvant)	**Ph3**
Tecentriq	+Tarceva or Alecensa	Ph1
Tecentriq	+chemo (SCLC)	**Ph3**
Tecentriq	+epacadostat*	Ph1

Melanoma

Tecentriq	+Zelboraf ±Cotellic	Ph1

Ovarian

Tecentriq	+rucaparib*	Ph1

Breast (TNBC & HER2+)

Tecentriq	+chemo (TNBC)	**Ph3**
Tecentriq	+Kadcyla or Herceptin+ Perjeta (HER2+)	Ph1
Tecentriq	+T-VEC*	Ph1
Tecentriq	+entinostat*	Ph2

RCC

Tecentriq	±Avastin	Ph2
Tecentriq	+Avastin	**Ph3**

Sarcoma

Tecentriq	+CMB305 (NY-ESO-1)*	Ph2

Colon

Tecentriq	+Cotellic (3L+)	**Ph3**
Tecentriq	+T-VEC*	Ph1

Hematological tumors

Tecentriq	±lenalidomide ±daratumumab*	(R/R MM)	Ph1
Tecentriq	±azacitidine	(MDS)	Ph1
Tecentriq	+Gazyva or +tazemetostat*	(R/R FL and DLBCL)	Ph1
Tecentriq	+Gazyva +polatuzumab	(R/R FL and DLBCL)	Ph2
Tecentriq	+Gazyva +lenalidomide	(R/R FL and DLBCL)	Ph1
Tecentriq	+Gazyva +bendamustin or CHOP	(1L FL and DLBCL)	Ph1
aCD20/CD3 TCB			Ph1
Tecentriq	+CD19 CAR-T*	(refractory aNHL)	Ph1

✓ = approved; *External collaborations; Other CIT NMEs besides Tecentriq

As of July 21, 2016

CIT portfolio with 10 NMEs

First read-outs for all NMEs expected in 2016/2017



	Compound 1	Compound 2	Phase	Readout**
2	aCD40	+ Tecentriq	Ph I (n=110)	2017
	aCD40	+ vanucizumab	Ph I (n=170)	2017
	aCD40	+ emactuzumab	Ph I (n=120)	2017
3	aCEA-IL2v FP	+ Tecentriq	Ph I (n=75)	2017
	aFAP-IL2v FP		Ph I (n=60)	2017
	aOX40		Ph I (n=400)	2017
	aOX40	+ Tecentriq	Ph I (n=360)	2017
5	vanucizumab		Ph II McCave (n=190)	2016
	vanucizumab	+ Tecentriq	Ph I (n=40)	2017
6	aCEA/CD3 TCB		Ph I (n=100)	2017
	aCEA/CD3 TCB	+ Tecentriq	Ph I (n=100)	2017
	aCD20/CD3 TCB		Ph I (n=170)	2017
7	emactuzumab	+ Tecentriq	Ph I (n=162)	2017
	IDOi	+ Tecentriq	Ph I (n=224)	2017
	aTIGIT	+ Tecentriq	Ph I (n=300)	2017

Chen and Mellman. Immunity 2013;
* CIT NMEs from partners in external collaborations; ** Outcome studies are event driven, timelines may change;
NME=new molecular entity; CIT=cancer immunotherapy; FP=fusion protein; TCB=T-cell bispecific;

H1 2016 results

Innovation

Outlook

2016 onwards: Significant launch activities



Outcome studies are event-driven: timelines may change. Standard approval timelines of 1 year assumed.

Additional key oncology presentations in 2016*

Copenhagen, 7-11 Oct

- **Tecentriq + Zelboraf + Cotellic:** Ph1 in 1L BRAF+ mM
- **Tecentriq:** Ph II update (*IMvigor 210*) in bladder cancer
- **Tecentriq:** Ph I in SCLC
- **Tecentriq**: Ph I in ovarian cancer
- **Tecentriq:** Ph III (*OAK*) in 2L NSCLC *(or IASLC)*
- **Tecentriq + Cotellic:** Ph 1 in CRC
- **ipatasertib:** Ph II *(A.Martin)* in 2L CRPC

San Diego, 3-6 Dec

- **Gazyva:** Ph III (*GOYA*) in 1L DLBCL (aNHL)
- **Gazyva:** Ph III *(GALLIUM)* in 1L FL (iNHL)
- **polatuzumab + Gazyva:** Ph II (*ROMULUS*) in R/R FL / DLBCL
- **polatuzumab + Gazyva + CHP:** Ph I in NHL
- **polatuzumab + Rituxan + CHP:** Ph I/II in 1L DLBCL (aNHL)
- **polatuzumab + Gazyva/Rituxan + bendamustin:** Ph I/II in R/R DLBCL (aNHL) and R/R FL (iNHL)
- **Venclexta + Rituxan +/- bedamustin:** Ph II (*CONTRALTO*) in R/R FL
- **Venclexta + Gazyva :** Ph III safety run-in in 1L CLL
- **Biomarker** data in MM and FL examining immune environment

Vienna, 4-7 Dec

- **Tecentriq:** Ph II 1L update (*BIRCH*) in PDL1+NSCLC
- **Tecentriq + Tarceva:** Ph I in NSCLC

San Antonio, 6-10 Dec

- **taselisib:** Ph II in mHER2-/ER+ BC

* Planned submissions (to be confirmed); Outcome studies are event driven, timelines may change

2016: Key late-stage news flow

	Compound	Indication	Milestone	
Regulatory	***Gazyva***	Rituxan-refractory iNHL	US/EU approval	✓
	Venclexta	R/R CLL with 17p deletion	US approval	✓
	OCREVUS	RMS/PPMS	US/EU filing	✓
	Tecentriq	Bladder cancer	US approval	✓
	Tecentriq	2/3L NSCLC	US approval	
	Alecensa	2L ALK+ NSCLC	EU CHMP opinion	
Phase III readouts*	***lebrikizumab***	Severe asthma	Ph III LAVOLTA I/II	✗
	Tecentriq	2/3L NSCLC	Ph III OAK	
	Gazyva	1L aNHL	Ph III GOYA	✗
	Gazyva	1L FL (iNHL)	Ph III GALLIUM	✓ new
	Perjeta + Herceptin	Adjuvant HER2+ BC	Ph III APHINITY	
	Actemra	Giant cell arteritis	Ph III GiACTA	✓
	Alecensa	1L ALK+ NSCLC	Ph III ALEX	early 2017
Phase II readouts*	***lebrikizumab***	Atopic dermatitis	Ph II TREBLE, ARBAN	data in-house
	Tecentriq	Bladder cancer	Ph II IMvigor 210 (1L)	✓
	Tecentriq + Avastin	1L Renal cancer	Ph II IMmotion 150	
	Venclexta + Rituxan	R/R FL (iNHL)	Ph II CONTRALTO	
	Venclexta + Rituxan/Gazyva	1L aNHL	Ph II CAVALLI	✓

* Outcome studies are event driven, timelines may change

Diagnostics Division

Roland Diggelmann

CEO Roche Diagnostics

HY 2016: Diagnostics Division sales

Growth driven by laboratory businesses

	HY 2016 CHFm	HY 2015 CHFm	Change in % CHF	Change in % CER
Diagnostics Division	**5,562**	**5,235**	**6**	**6**
Professional Diagnostics	3,233	2,972	9	9
Diabetes Care	998	1,057	-6	-4
Molecular Diagnostics	903	832	9	8
Tissue Diagnostics	428	374	14	12

CER=Constant Exchange Rates; Underlying growth of Molecular Diagnostics excluding sequencing business: +2%

HY 2016: Diagnostics regional sales

Growth contribution by all regions



+23% growth in E7 countries[2]

[1] Europe, Middle East and Africa; [2] Brazil, China, India, Mexico, Russia, South Korea, Turkey
All growth rates at Constant Exchange Rates

HY 2016: Diagnostics highlights
Growth driven by immunodiagnostic products



- Driven by immunodiagnostics (+14%) and clinical chemistry (+6%)
- Spillover of US reimbursement cuts to private sector
- Virology (+12%) incl. HPV (+16%)
- Advanced staining portfolio (+9%); primary staining (+16%)

[1] Underlying growth of Molecular Diagnostics excluding sequencing business: +2%
CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa

HY 2016: Diagnostics Division

Core operating profit growth impacted by new product launches, investments in R&D

	HY 2016 CHFm	HY 2016 % sales
Sales	**5,562**	**100.0**
Royalties & other op. inc.	60	1.1
Cost of sales	-2,560	-46.1
M & D	-1,270	-22.8
R & D	-651	-11.7
G & A	-134	-2.4
Core operating profit	**1,007**	**18.1**



CER=Constant Exchange Rates

Launch of cobas e801 immunoassay analyser

Maximising laboratory productivity and efficiency

cobas® 8000 modular analyser series

- Double throughput with same footprint
- Fastest time to result
- Highest accuracy
- Lower blood sample volume

Launch of CoaguChek INRange

First wireless self-testing for patients in VKA[1] therapy

- **New:** connectivity to healthcare professionals improving patient convenience
- Target market: ~CHF 670m (+5% CAGR)

[1] VKA: vitamin K antagonist

Wan et al (2008). Circ Cardiovasc Qual Outcomes 1:84–91; Bloomfield et al (2011). Ann Int Med 154:472–482

First liquid biopsy test approved by FDA
cobas EGFR v2 CDx for Tarceva

- Test can utilise plasma and tissue sample

cobas 4800

- Leverages cobas 4800 platform

Immunotherapy diagnostics

PD-L1 test approved for bladder cancer

BenchMark ULTRA

VENTANA PD-L1 (SP142)
CDx Assay



- FDA approved SP142 to predict bladder cancer patient response to Tecentriq
- PD-L1 IHC expression shown to correlate with and predict therapeutic outcomes
- Available on BenchMark ULTRA platform: Large global installed base

Key launches 2016

	Area	Product	Market
Instruments / Devices	***Central Laboratory***	cobas 8000 <e 801> – high throughput immunochemistry analyzer	EU ✓
		cobas c 513 – high throughput dedicated HbA1c analyzer	US
	Point of Care	CoaguChek INRange (Zenith) – modified analyzer for intuitive self testing with full blue tooth connectivity	EU ✓
	Sequencing	Roche SMRT Sequencer – single molecule sequencer for clinical research (in collaboration with Pacific Biosciences)	WW
	Diabetes Care	Accu-Chek Guide – next-generation blood glucose monitoring system	EU
		Accu-Chek Insight CGM – new high-performance continuous glucose monitoring system	EU
Tests / Assays	***Virology***	cobas 6800/8800 HIV Qual – early Infant Diagnosis and Confirmatory HIV Test	EU
	HPV / Microbiology	cobas 6800/8800 CT/NG – fully automated solution for screening and diagnosis of *Chlamydia trachomatis* and *Neisseria gonorrhoeae in symptomatic & asymptomatic patients*	EU
	Point of Care	cobas Liat Influenza A/B plus RSV (CLIA) – automated multiplex real time RT-PCR assay for qualitative detection and discrimination of Influenza A virus, Influenza B virus and respiratory syncytial virus (RSV)	US
	Sequencing	ctDNA oncology panels – liquid biopsy for circulating tumor DNA for cancer therapy selection	US
	Companion Diagnostics	PD-L1 (SP142) for Bladder Cancer* – companion diagnostic for atezolizumab	US ✓
		PD-L1 (SP142) for NSCLC* – companion diagnostic for atezolizumab	US

* achieve commercial readiness, dependent on Pharma label and approval

Finance

Alan Hippe

Chief Financial Officer

HY 2016: Core EPS growth above sales growth

Business

- Strong sales growth of +5%[1] and Core operating profit up +5%[1]
- Core EPS growth +5%[1]

Cash flow

- Significant cash generation (Op. FCF of CHF 5.5bn), impact of launch activities
- Increased net debt vs. YE 2015 due to outflow of dividends

Capital markets update – New bond redemption

- Final "make-whole" call
  - USD: 857m nominal outstanding (maturity in March 2019) – coupon 6.0% s.a.[2]
    - Loss on redemption of CHF 96m

[1] At Constant Exchange Rates (CER); [2] s.a.=semi-annual coupon

HY 2016: Group performance

Core EPS growth +5%

	HY 2016 CHFm	HY 2015 CHFm	Change in % CHF	Change in % CER	Excl. PSI*
Sales	**25,022**	**23,585**	**6**	**5**	
Core operating profit	**9,854**	**9,236**	**7**	**5**	**0**
as % of sales	*39.4*	*39.2*			
Core net income	**6,761**	**6,320**	**7**	**5**	**0**
as % of sales	*27.0*	*26.8*			
Core EPS (CHF)	**7.74**	**7.22**	**7**	**5**	**0**
IFRS net income	**5,467**	**5,249**	**4**	**3**	
Operating free cash flow	**5,487**	**6,525**	**-16**	**-19**	
as % of sales	*21.9*	*27.7*			
Free cash flow	**2,849**	**3,966**	**-28**	**-32**	
as % of sales	*11.4*	*16.8*			

CER=Constant Exchange Rates
* Past service income; growth rates at CER

Exchange rate impact on sales growth

Positive impact from USD, JPY and EUR



CER=Constant Exchange Rates

HY 2016: Core profit before tax
+5% CER



2016 outlook

- Core EPS growth ahead of sales growth
- Low to mid-single digit Group sales growth

CER=Constant Exchange Rates (average full year 2015)

HY 2016: Group operating performance

Core operating profit growth +5%

	HY 2016 CHFm	HY 2016 % sales
Sales	**25,022**	**100.0**
Royalties & other op. inc.	986	3.9
Cost of sales	-6,428	-25.7
M & D	-4,309	-17.2
R & D	-4,780	-19.1
G & A	-637	-2.5
Core operating profit	**9,854**	**39.4**

PSI* = +426



CER=Constant Exchange Rates
* Past service income

HY 2016: Impact of past service income (PSI)

in CHFm	Group	Pharma	Diagnostics	Corporate
General & administration	426	310	77	39
Operating profit	**426**	**310**	**77**	**39**
Margin impact	*+1.7%p*	*+1.6%p*	*+1.4%p*	
CER growth impact	*+4.6%p*	*+3.7%p*	*+7.5%p*	
Deferred taxes	-85			
Net income	**341**			
CER growth impact	*+5.4%p*			
Core EPS (CHF)	**0.40**			
CER growth impact	*+5.4%p*			

CER=Constant Exchange Rates

HY 2016: Strong core operating profit and margin

Investments in development, pre-launch & launch activities



[1] At CER=Constant Exchange Rates

HY 2016: Core net financial result

Improvement driven by lower interest expenses



CER=Constant Exchange Rates

Balance sheet as at 30 June 2016

Equity ratio and net debt to assets unchanged YoY



CER=Constant Exchange Rates

HY 2016: Operating free cash flow
Impacted by launches



[1] At CER=Constant Exchange Rates

Free cash flow: Reporting aligned to peers

Dividend payments excluded from FCF

CHFm	FY 2014	FY 2015		Revised reporting FY 2014	Revised reporting FY 2015
Operating free cash flow	15,778	14,872		15,778	14,872
Treasury activities	-756	-870		-756	-870
Taxes paid	-2,982	-3,696		-2,982	-3,696
Dividends paid	-6,718	-6,954		-	-
Free cash flow	5,322	3,352		12,040	10,306
Net debt at beginning of period	-6,708	-14,011		-6,708	-14,011
Free cash flow	5,322	3,352		12,040	10,306
Dividends paid	-	-		-6,718	-6,954
Other (mainly business combinations)	-12,625	-3,421		-12,625	-3,421
Change in net debt	-7,303	-69		-7,303	-69
Net debt at end of period	-14,011	-14,080		-14,011	-14,080

HY 2016: Group net debt development

Higher net debt due to dividend payment



Positive currency impact on Swiss Franc results expected in 2016





Assuming the 30 June 2016 exchange rates remain stable until end of 2016, 2016 impact is expected to be (%p):

	Q1	HY	Sep YTD	FY
Sales	1	1	1	1
Core operating profit		2		1
Core EPS		2		2

2016 outlook

Group sales growth[1]	Low to mid-single digit
Core EPS growth[1]	Ahead of sales growth
Dividend outlook	Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER)

Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group HY 2016 results

Diagnostics

Foreign exchange rate information

Changes to the development pipeline
HY 2016 update

New to Phase I	New to Phase II	New to Phase III	New to Registration
4 NMEs transitioned from Ph0 **RG6000** – ALS **RG6058** TIGIT+Tecentriq – solid tumors **RG6100** Tau MAb – Alzheimer's disease **RG7990** – asthma **3 AIs** **RG7155** emactuzumab + CD40 iMAb – solid tumors **RG7446** Tecentriq – NMIBC **RG7446** Tecentriq + HMA – MDS	**1 NME transitioned from Ph1** **RG7625** Cat S antag – autoimmune diseases **1 AI reflected as NME following discontinuation of the lead indication** **RG3637** lebrikizumab in atopic dermatitis	**5 AIs** **RG435** Avastin – mesothelioma **RG7421** Cotellic + Tecentriq – CRC 3L **RG7446** Tecentriq + chemo – cis-ineligible mUC 1L **RG7446** Tecentriq + chemo – extensive stage SCLC 1L **RG7601** Venclexta + bortezomib – MM relapsed/refractory **1 NME reflected as Roche global program following in-licensing from Chugai** **RG6168** IL-6R MAb – neuromyelitis optica	**1 NME transitioned from Ph3** **RG1594** OCREVUS® – PPMS & RMS **1 AI transitioned from Ph3** **RG435** Avastin – rel. ovarian ca. Pt-sensitive
Removed from Phase I	**Removed from Phase II**	**Removed from Phase III**	**Removed from Registration**
1 NME **RG6024** Flu B MAb – influenza B		**3 AIs** **RG7159** Gazyva – DLBCL 1L **RG1273** Perjeta + Herceptin – HER2+ mBC 2L **RG3502** Kadcyla + Perjeta – HER2+ BC neoadj **1 NME (new NME in Ph2 in atopic dermatitis)** **RG3637** lebrikizumab – severe asthma	**2 AI following European approval** **RG435** Avastin + Tarceva – EGFR mut+ NSCLC **RG7159** Gazyva – iNHL rituximab-ref

Status as of July 21, 2016

Roche Group development pipeline

Phase I
(45 NMEs+23 AIs)

RG6016	LSD1 inh	AML
RG6047	SERD (2)	ER+(HER2-neg) mBC
RG6058	TIGIT+Tecentriq	solid tumors
RG6061	HIF1 alpha LNA	solid tumors
RG6078	IDO inh	solid tumors
RG6078	IDO inh+Tecentriq	solid tumors
RG6146	BET inh	oncology
RG7155	emactuzumab+Tecentriq	s. tumors
RG7155	emactuzumab + CD40 iMAb	s. tumors
RG7159	Gazyva multiple combos	heme indications
RG7304	Raf & MEK dual inh	solid tumors
RG7386	FAP-DR5 biMAb	solid tumors
RG7446	Tecentriq	solid tumors
RG7446	Tecentriq+Zelboraf+/-Cotellic	melanoma
RG7446	Tecentriq±Avastin±chemo	HCC-GC-PaC
RG7446	Tecentriq±Avastin±chemo	solid tumors
RG7446	Tecentriq+Cotellic	solid tumors
RG7446	Tecentriq +ipi/IFN	solid tumors
RG7446	Tecentriq+Tarceva/Alecensa	NSCLC
RG7446	Tecentriq +Gazyva	lymphoma
RG7446	Tecentriq±lenalidomide±daratumumab	MM
RG7446	Tecentriq+ K/HP	HER2+ BC
RG7446	Tecentriq	NMIBC
RG7446	Tecentriq+HMA	MDS
RG7461	FAP IL2v FP	solid tumors
RG7601	Venclexta	heme indications
RG7601	Venclexta +Gazyva	CLL
RG7601	Venclexta+Cotellic/idasanutlin	AML
RG7741	ChK1 inh	solid tum & lymphoma
RG7775	MDM2 (4) IV prodrug	AML
RG7802	CEACD3 TCB±Tecentriq	s. tumors
RG7813	*CEA IL2v FP+Tecentriq	s. tumors
RG7828	CD20/CD3 biMAb	heme tumors
RG7841	Ly6E ADC	solid tumors
RG7842	ERK inh + Cotellic	solid tumors
RG7876	CD40 iMAb+Tecentriq	solid tumors
RG7876	CD40 iMAb+vanucizumab	solid tumors
RG7882	ADC	ovarian ca
RG7888	OX40 MAb	solid tumors
RG7888	OX40 MAb + Tecentriq	solid tumors
RG7986	ADC	r/r NHL
RG3616	Erivedge+Esbriet	IPF
RG3616	Erivedge+ruxolitinib	myelofibrosis
RG6069	-	fibrosis
RG6125	Cadherin-11 MAb	RA
RG6149	ST2 MAb	asthma
RG7159	obinutuzumab	renal transplant
RG7845	BTK inh	autoimmune diseases
RG7880	IL-22Fc	inflammatory diseases
RG7990	-	asthma
RG6080	DBO β-lactamase inh	bact. infections
RG7834	-	HBV
RG7861	anti-S. aureus TAC	infect. diseases
RG7944	therapeutic vaccine	HBV
RG7992	FGFR1/KLB MAb	metabolic diseases
RG6000	-	ALS
RG6029	Nav1.7 inh (2)	pain
RG6100	Tau MAb	Alzheimer's disease
RG7203	PDE10A inh	schizophrenia
RG7800	SMN2 splicer	spinal muscular atrophy
RG7893	Nav1.7 inh	pain
RG7906	-	psychiatric disorders
RG7916	SMN2 splicer(2)	spinal muscular atrophy
RG7935	a-synuclein MAb	Parkinson's Disease
IONIS	ASO	Huntington's Disease
CHU	PTH1 recep. ago	hypoparathyroidism
CHU	-	hyperphosphatemia
RG4929	-	glaucoma

* NN: cergutuzumab amunaleukin

Phase II
(18NMEs+11 AIs)

RG3502	Kadcyla	HER2+ NSCLC
RG6046	SERD	ER+(HER2-neg) mBC
RG7221	vanucizumab	mCRC
RG7421	Cotellic+paclitaxel	TNBC
RG7440	ipatasertib	solid tumors
RG7596	polatuzumab vedotin	heme tumors
RG7601	Venclexta	DLBCL
RG7601	Venclexta + Rituxan	FL rel/ref
RG7604	taselisib	NSCLC sq 2L
RG7604	taselisib+letrozole	(HER2-) BC neoadj
RG7686	codrituzumab	hepatocellular carcinoma
RG3637	lebrikizumab +/- Esbriet	IPF
RG3637	lebrikizumab	atopic dermatitis
RG3637	lebrikizumab	COPD
RG7159	obinutuzumab	lupus nephritis
RG7625	Cat-S antag	autoimmune diseases
CHU	nemolizumab (IL-31R)	atopic dermatitis
CHU	nemolizumab (IL-31R)	pruritus dialysis pts
PRO	VAP-1 inh	inflammatory disease
RG6152	CAP endonuclease inh	influenza
RG7227	danoprevir	HCV
RG7745	Flu A MAb	influenza A
RG7795	TLR7 agonist	HBV
CHU	URAT1 inh	gout
RG1662	basmisanil	Down's syndrome
RG6083	olesoxime	spinal muscular atrophy
RG7314	V1 receptor antag	autism
RG3645	ranibizumab PDS	wAMD
RG7716	VEGF-ANG2 biMAb	wAMD

atezolizumab is marketed under the brand name Tecentriq

New Molecular Entity (NME)
Additional Indication (AI)

Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

RG-No Roche/Genentech managed
CHU Chugai managed
IONIS IONIS managed
PRO Proximagen managed

Status as July 21, 2016

Roche Group development pipeline

Phase III
(8 NMEs + 29 AIs)

RG435[1]	Avastin	glioblastoma 1L
RG435	Avastin	mesothelioma
RG1273	Perjeta+Herceptin	HER2+ BC adj
RG1273	Perjeta+Herceptin	HER2+gastric ca 1L
RG3502	Kadcyla	HER2+ BC adj
RG3502	Kadcyla + Perjeta	HER2+ BC adj
RG6013	emicizumab	hemophilia A
RG7159	Gazyva	follicular lymphoma 1L
RG7204	Zelboraf	melanoma adj
RG7421	Cotellic + Tecentriq	CRC 3L
RG7446	Tecentriq+chemo	NSCLC non-sq. 1L
RG7446	Tecentriq+chemo+Avastin	NSCLC non-sq. 1L
RG7446	Tecentriq+chemo+pemetrexed	NSCLC non-sq.1L
RG7446	Tecentriq+chemo	NSCLC sq. 1L
RG7446	Tecentriq Dx+	NSCLC sq. & non sq. 1L
RG7446	Tecentriq	NSCLC adj
RG7446	Tecentriq+abraxane	TNBC
RG7446	Tecentriq+Avastin	RCC
RG7446	Tecentriq	muscle inv. bladder ca adj
RG7446	*Tecentriq+chemo	cis-ineligible mUC
RG7446	Tecentriq+chemo	extens. stage SCLC 1L
RG7601	Venclexta+Rituxan	CLL rel/refract
RG7601	Venclexta+Gazyva	CLL 1L
RG7601	Venclexta+bortezomib	MM rel/refract
RG7604	taselisib+fulvestrant	PIK3CAmut ER+(HER2-)mBC
RG7388	idasanutlin	AML
RG7853	Alecensa	ALK+ NSCLC 1L

RG105	MabThera	pemphigus vulgaris
RG1569	Actemra	giant cell arteritis
RG1569	Actemra	systemic sclerosis
RG7413	etrolizumab	ulcerative colitis
RG7413	etrolizumab	Crohn's disease
CHU	Actemra	large-vessel vasculitis
RG1450	gantenerumab	Alzheimer's
RG6168	IL-6R MAb	neuromyelitis optica
RG7412	crenezumab	Alzheimer's
RG7417	lampalizumab	geographic atrophy

* Expect FPI Q3.2016

Registration
(3 NMEs + 3AIs)

RG105[2]	MabThera SC	CLL
RG435[3]	Avastin	rel. ovarian ca. Pt-sensitive
RG7446[4]	Tecentriq	mUC 2L
RG7446[5]	Tecentriq	NSCLC 2L+
RG7853[6]	Alecensa	ALK+ NSCLC 2L
RG1594	OCREVUS®	PPMS & RMS

atezolizumab is marketed under the brand name Tecentriq

1 US only
2 Approved in EU – Filing US pending
3 EU chemo backbone extension filing pending
4 Phase 3 ongoing – Approved in the US
5 Phase 3 ongoing
6 Approved in the US and Japan

New Molecular Entity (NME)
Additional Indication (AI)
Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

RG-No Roche/Genentech managed
CHU Chugai managed
IONIS IONIS managed
PRO Proximagen managed
RG105 MabThera is branded as Rituxan in US and Japan
RG1569 Actemra is branded as RoActemra in EU
RG7159 Gazyva is branded as Gazyvaro in EU

Status as of July 21, 2016

NME submissions and their additional indications

Projects currently in phase 2 and 3



Unless stated otherwise, submissions are planned to occur in US and EU

✓indicates a submission which has occurred with regulatory action pending ; *approved in US

Status as of July 21, 2016

Submissions of additional indications for existing products

Projects currently in phase 2 and 3



✓ indicates submission to health authorities has occurred
* Approved in EU

Unless stated otherwise, submissions are planned to occur in US and EU.
Status as of July 21, 2016

Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other
NME

Major granted and pending approvals 2016



Status as of July 21, 2016

Roche Group Development pipeline
Combinations

Phase I
(5 NMEs + 19 AIs)

RG6058	TIGIT+Tecentriq	solid tumors
RG6078	IDO inh + Tecentriq	solid tumors
RG7155	emactuzumab+Tecentriq	s. tumors
RG7155	emactuzumab + CD40 iMAb	s. tumors
RG7159	Gazyva multiple combos	heme indications
RG7446	Tecentriq+Zelboraf+/-Cotellic	melanoma
RG7446	Tecentriq+Avastin+chemo	HCC-GC-PaC
RG7446	Tecentriq±Avastin±chemo	solid tumors
RG7446	Tecentriq+Cotellic	solid tumors
RG7446	Tecentriq +ipi/IFN	solid tumors
RG7446	Tecentriq+Tarceva/ Alecensa	NSCLC
RG7446	Tecentriq+Gazyva	lymphoma
RG7446	Tecentriq±lenalidom.±daratumumab	MM
RG7446	Tecentriq + K/HP	HER2+BC
RG7446	Tecentriq+HMA	MDS
RG7601	Venclexta+Gazyva	CLL
RG7601	Venclexta+Cotellic/idasanutlin	AML
RG7802	CEA CD3 TCB+Tecentriq	s. tumors
RG7813	*CEA IL2v FP+Tecentriq	s. tumors
RG7876	CD40 MAb+Tecentriq	s. tumors
RG7876	CD40 iMAb+vanucizumab	solid tumors
RG7888	OX40 MAb +Tecentriq	s. tumors
RG3616	Erivedge+Esbriet	IPF
RG3616	Erivedge+ruxolitinib	myelofibrosis

Phase II
(4 AIs)

RG7421	Cotellic+paclitaxel	TNBC
RG7601	Venclexta+Rituxan	FL rel/ref
RG7604	taselisib+letrozole	(HER2-)BC neoadj
RG3637	lebrikizumab +/- Esbriet	IPF

Phase III
(15 AIs+1 NME)

RG1273	Perjeta+Herceptin	H ER2+ BC adj
RG1273	Perjeta+Herceptin	HER2+gastric ca 1L
RG3502	Kadcyla + Perjeta	HER2+ BC adj
RG7421	Cotellic + Tecentriq	CRC 3L
RG7446	Tecentriq+chemo	SCLC non-sq. 1L
RG7446	Tecentriq+chemo+Avastin	NSCLC non-sq. 1L
RG7446	Tecentriq+chemo+pemetrexed	NSCLC non-sq.1L
RG7446	Tecentriq+chemo	NSCLC sq. 1L
RG7446	Tecentriq+abraxane	TNBC
RG7446	Tecentriq+Avastin	RCC
RG7446	Tecentriq+chemo	cis-ineligible mUC 1L
RG7446	Tecentriq+chemo extens. stage	SCLC 1L
RG7601	Venclexta+Rituxan	CLL rel/ref
RG7601	Venclexta +Gazyva	CLL 1L
RG7601	Venclexta+bortezomib	MM rel/refract
RG7604	taselisib+fulvestrant	PIK3CA mut ER+(HER2-neg)mBC

New Molecular Entity (NME)
Additional Indication (AI)

Oncology
Immunology

RG-No **Roche Genentech managed**

*INN: cergutuzumab amunaleukin

atezolizumab is marketed under the brand name Tecentriq

Status as of July 21, 2016

Cancer immunotherapy pipeline overview

Phase I
(9 NMEs + 25 AIs)

RG6058	TIGIT+Tecentriq	solid tumors
RG6078	IDO inh	solid tumors
RG6078	IDO inh+Tecentriq	solid tumors
RG7155	emactuzumab+Tecentriq	solid tumors
RG7155	emactuzumab + CD40 iMAb	s. tumors
RG7446	Tecentriq	solid tumors
RG7446	Tecentriq+Zelboraf+/-Cotellic	melanoma
RG7446	Tecentriq±Avastin±chemo	HCC-GC-PaC
RG7446	Tecentriq±Avastin±chemo	solid tumors
RG7446	Tecentriq+ Cotellic	solid tumors
RG7446	Tecentriq +ipi/IFN	solid tumors
RG7446	Tecentriq+Tarceva/Alecensa	NSCLC
RG7446	Tecentriq+Gazyva	lymphoma
RG7446	Tecentriq±lenalidom.±daratumumab	MM
RG7446	Tecentriq+ K/HP	HER2+ BC
RG7446	Tecentriq	NMIBC
RG7446	Tecentriq+HMA	MDS
RG7461	FAP IL2v FP	solid tumors
RG7802	CEA CD3 TCB+Tecentriq	s. tumors
RG7813	CEA IL2v FP+Tecentriq	s. tumors
RG7828	CD20/CD3 biMAb	heme tumors
RG7876	CD40 iMAb+Tecentriq	s. tumors
RG7876	CD40 iMAb+vanucizumab	solid tumors
RG7888	OX40 MAb	solid tumors
RG7888	OX40 MAb+Tecentriq	s. tumors
*INCY	Tecentriq(atezo)+IDO inh	solid tumors
*CLDX	Tecentriq(atezo)+varlilumab	s. tumors
*CRVS	Tecentriq (atezo)+CPI-4444	s. tumors
*KITE	Tecentriq (atezo)+KTE-019	r/r DLBCL
*AMGN	Tecentriq+talimogene laherp	TNBC, CRC
*JNJ	Tecentriq ±daratum.±lenalido.	s. tumors
*CLVS	Tecentriq(atezo)+rucaparib	ovarian ca
Epizyme	Tecentriq+tazemetostat	r/r DLBCL
Astex	Tecentriq+guadecitabine	AML

Phase II
(2 AIs)

IMDZ	Tecentriq+NY-ESO-1	soft tissue sarcoma
SNDX	Tecentriq(atezo)+entinostat	TNBC

Phase III
(12 AIs)

RG7421	Cotellic + Tecentriq	CRC 3L
RG7446	Tecentriq+chemo	NSCLC non-sq. 1L
RG7446	Tecentriq+chemo+Avastin	NSCLC non-sq 1L
RG7446	Tecentriq+chemo+pemetrexed	NSCLC non-sq1L
RG7446	Tecentriq+chemo	NSCLC sq 1L
RG7446	Tecentriq Dx+	SCLC sq & non sq. 1L
RG7446	Tecentriq	NSCLC adj
RG7446	Tecentriq+abraxane	TNBC
RG7446	Tecentriq+Avastin	RCC
RG7446	Tecentriq	muscle inv. bladder ca adj
RG7446	Tecentriq+chemo	cis-ineligible mUC 1L
RG7446	Tecentriq+chemo	extens. stage SCLC 1L

Registration
(1 NME + 1 AI)

RG7446 [2]	Tecentriq	mUC 2L
RG7446 [3]	Tecentriq	NSCLC 2L+

1 FPI expected Q4 2016
2 Phase 3 ongoing - Approved in the US
3 Phase 3 ongoing

New Molecular Entity (NME)
Additional Indication (AI)

Oncology

RG-No Roche Genentech managed

atezolizumab is marketed under the brand name Tecentriq

*external collaborations: INCY- Incyte INCB024360, CLDX - Celldex CD27 MAb; CLVS – Clovis PARPi, CRVS – Corvus CPI-444, KITE – Kite KTE-C19, AMGN – Amgen oncolytic virus, JNJ – Janssen CD38 MAb., IMDZ – Immune Design CMB305, SNDX – Syndax HDACi

Status as of July 21, 2016

Doing now what patients need next